Conditions: Epilepsy
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 21
Healthy volunteers: no

Brief summary:
The main purpose of this trial is to allow continued access to pregabalin to Canadian subjects who participated in global pregabalin epilepsy studies 1008-010; 1008-035; 1008-114 and 1008-164 and to continue to study the long term safety of pregabalin administered as adjunctive therapy at dosages from 150 mg/day to 600 mg/day in Canadian subjects with refractory partial seizures.

Detailed description:

Arms:
arm 1: open label treatment

Interventions: intervention 1: pregabalin (LYRICA)
Intervention descriptions: intervention 1: 150 mg up to a maximum of 600 mg per day bid or tid as required

Protocol document: